News | December 04, 2025
Philips unveils helium-free 3.0T MRI innovation at RSNA 2025
The BlueSeal Horizon 3.0T platform incorporates advanced magnet technology
The BlueSeal Horizon 3.0T platform incorporates advanced magnet technology
The platform integrates with CT imaging and uses deep learning models to generate a 3D digital twin of lung anatomy
The MUSE system offers a minimally invasive solution for treating gastroesophageal reflux disease
The update reflects long-term clinical trial data showing that many patients with mCSCC or laCSCC experienced lasting responses
Pfizer and Valneva have been collaborating on VLA15’s development and commercialization since April 2020
The approvals target adult MIBC patients who are ineligible for cisplatin-based chemotherapy
This is the first and only subcutaneous immune checkpoint inhibitor available in Europe
EBITDA was Rs. 2,359.6 crore in the quarter ended September 30, 2025
The trial will evaluate safety endpoints including dose-limiting toxicities and adverse events
Adjusted EBITDA increased by 12.3 per cent to $531 million, up from $516 million in the same period last year
Subscribe To Our Newsletter & Stay Updated
